MoonLake Immunotherapeutics (NASDAQ:MLTX) Insider Kristian Reich Sells 130,000 Shares of Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $15.08, for a total value of $1,960,400.00. Following the completion of the sale, the insider owned 72,908 shares of the company’s stock, valued at approximately $1,099,452.64. The trade was a 64.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Kristian Reich also recently made the following trade(s):

• On Tuesday, December 9th, Kristian Reich sold 72,908 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $14.43, for a total transaction of $1,052,062.44.

MoonLake Immunotherapeutics Trading Up 0.4%

MLTX opened at $14.61 on Thursday. The firm has a 50 day simple moving average of $11.36 and a 200 day simple moving average of $36.10. MoonLake Immunotherapeutics has a fifty-two week low of $5.95 and a fifty-two week high of $62.75. The company has a market cap of $938.40 million, a price-to-earnings ratio of -4.40 and a beta of 1.21. The company has a debt-to-equity ratio of 0.25, a current ratio of 8.50 and a quick ratio of 8.50.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last released its earnings results on Wednesday, November 5th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.21). During the same period in the previous year, the business earned ($0.56) EPS. On average, sell-side analysts anticipate that MoonLake Immunotherapeutics will post -1.79 earnings per share for the current year.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several institutional investors have recently added to or reduced their stakes in MLTX. Alliancebernstein L.P. boosted its stake in MoonLake Immunotherapeutics by 17.8% in the 2nd quarter. Alliancebernstein L.P. now owns 1,138,022 shares of the company’s stock worth $53,715,000 after purchasing an additional 171,932 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in shares of MoonLake Immunotherapeutics in the third quarter valued at about $6,922,000. Hood River Capital Management LLC boosted its position in shares of MoonLake Immunotherapeutics by 1.9% during the second quarter. Hood River Capital Management LLC now owns 675,445 shares of the company’s stock worth $31,881,000 after buying an additional 12,462 shares during the period. Nuveen LLC bought a new position in shares of MoonLake Immunotherapeutics during the first quarter worth about $26,308,000. Finally, Vestal Point Capital LP raised its position in MoonLake Immunotherapeutics by 175.0% in the 2nd quarter. Vestal Point Capital LP now owns 550,000 shares of the company’s stock valued at $25,960,000 after buying an additional 350,000 shares during the last quarter. 93.85% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on MLTX shares. Guggenheim dropped their price objective on MoonLake Immunotherapeutics from $80.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, September 30th. Needham & Company LLC lowered their price target on MoonLake Immunotherapeutics from $66.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 30th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $7.00 price target on shares of MoonLake Immunotherapeutics in a research report on Wednesday, October 1st. Royal Bank Of Canada reissued a “sector perform” rating and set a $10.00 price target (down from $67.00) on shares of MoonLake Immunotherapeutics in a research report on Monday, September 29th. Finally, Jefferies Financial Group cut shares of MoonLake Immunotherapeutics from a “buy” rating to a “hold” rating and set a $8.00 price objective for the company. in a research report on Monday, September 29th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $30.25.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.